OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @GreatDebatesCME and @LLMCongress.

Oncology Learning Network

@OncLearnNetwork

Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @GreatDebatesCME and @LLMCongress.

The patient says they feel fine. You notice what they don’t. A cough that changes. Fatigue that runs deeper. At #OLNAPPInstitute, Sri Kota shares practical ways to identify & manage ADC toxicities early so care stays on track. hubs.ly/Q03VlRrR0 #OncologyAPPs #APPeducation

OncLearnNetwork's tweet image. The patient says they feel fine. You notice what they don’t. A cough that changes. Fatigue that runs deeper.

At #OLNAPPInstitute, Sri Kota shares practical ways to identify & manage ADC toxicities early so care stays on track.
hubs.ly/Q03VlRrR0

#OncologyAPPs #APPeducation

New insights from #SNO25: Updated molecular analyses from the phase 3 ECOG-ACRIN #E3F05 trial demonstrated that the addition of #temozolomide to radiation significantly improved overall survival in grade 2 #glioma. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. New insights from #SNO25: Updated molecular analyses from the phase 3 ECOG-ACRIN #E3F05 trial demonstrated that the addition of #temozolomide to radiation significantly improved overall survival in grade 2 #glioma. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

New insights from #SNO25: 3D volumetric RANO provided superior correlation with outcomes vs 2D RANO in patients with IDH1/2-mutant diffuse #glioma treated with #vorasidenib in the #INDIGO trial. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. New insights from #SNO25: 3D volumetric RANO provided superior correlation with outcomes vs 2D RANO in patients with IDH1/2-mutant diffuse #glioma treated with #vorasidenib in the #INDIGO trial. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

Yi-Bin Chen, MD, Massachusetts General Hospital, discusses the treatment course of a patient with chronic GVHD after receipt of an allogeneic stem cell transplant for IDH2-Mutated AML. Learn more: hubs.ly/Q03VsX4n0

OncLearnNetwork's tweet image. Yi-Bin Chen, MD, Massachusetts General Hospital, discusses the treatment course of a patient with chronic GVHD after receipt of an allogeneic stem cell transplant for IDH2-Mutated AML. Learn more: hubs.ly/Q03VsX4n0

Oncology Learning Network reposted

Watch Dr. Jia Ruan talk about emerging targeted therapies for peripheral T-cell #Lymphoma in this @OncLearnNetwork video from #LLMCongress: bit.ly/3X89LPO


The FDA granted approval to pembrolizumab or #pembrolizumab and #berahyaluronidase alfa-pmph and enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for patients with muscle invasive bladder cancer. Learn more: hubs.ly/Q03VrRxQ0

OncLearnNetwork's tweet image. The FDA granted approval to pembrolizumab or #pembrolizumab and #berahyaluronidase alfa-pmph and enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for patients with muscle invasive bladder cancer. Learn more: hubs.ly/Q03VrRxQ0

New insights from #AMP25: A 153-gene targeted fusion panel uncovered novel gene fusions, including lncRNA fusion partners, across diverse solid tumors. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. New insights from #AMP25: A 153-gene targeted fusion panel uncovered novel gene fusions, including lncRNA fusion partners, across diverse solid tumors. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

If your day revolves around keeping patients on track through each phase of treatment, this one’s for you. Join Jeannine Brant at #OLNAPPInstitute to explore how structured pathways can simplify coordination across every stage. hubs.ly/Q03VlNRn0 #APPs #OncologyAPPs

OncLearnNetwork's tweet image. If your day revolves around keeping patients on track through each phase of treatment, this one’s for you.

Join Jeannine Brant at #OLNAPPInstitute to explore how structured pathways can simplify coordination across every stage.

hubs.ly/Q03VlNRn0

#APPs #OncologyAPPs

New findings from #AMP2025: The iPLEX HS Lung Panel from @Agena_Bio demonstrated robust analytical accuracy and rapid detection of actionable mutations across 70 recurrent variants in lung cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. New findings from #AMP2025: The iPLEX HS Lung Panel from @Agena_Bio demonstrated robust analytical accuracy and rapid detection of actionable mutations across 70 recurrent variants in lung cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/…
 
#medtwitter #onctwitter

New findings from #AMP25: According to results from a retrospective analysis, MET exon 2 skipping mutations may reflect a self-regulatory mechanism threshold in #NSCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. New findings from #AMP25: According to results from a retrospective analysis, MET exon 2 skipping mutations may reflect a self-regulatory mechanism threshold in #NSCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

For patients with newly diagnosed primary central nervous system #DLBCL, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety. Learn more: hubs.ly/Q03Vht-40

OncLearnNetwork's tweet image. For patients with newly diagnosed primary central nervous system #DLBCL, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety. Learn more: hubs.ly/Q03Vht-40

Longer-term results from the #INDIGO trial: #Vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency in grade 2 IDH1/2-mutant diffuse #glioma. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. Longer-term results from the #INDIGO trial: #Vorasidenib continues to demonstrate clinical benefit and reductions in tumor volume and seizure frequency in grade 2 IDH1/2-mutant diffuse #glioma. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

Based on results from the phase 3 #DeLLphi304 trial, the @US_FDA has approved #tarlatamab for patients with extensive-stage #SCLC who experience disease progression on or after platinum-based #chemotherapy. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a… #medtwitter #onctwitter

OncLearnNetwork's tweet image. Based on results from the phase 3 #DeLLphi304 trial, the @US_FDA has approved #tarlatamab for patients with extensive-stage #SCLC who experience disease progression on or after platinum-based #chemotherapy. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a…

#medtwitter #onctwitter

The FDA has granted accelerated approval to #sevabertinib for adults with locally advanced or metastatic non-squamous #NSCLC harboring HER2 (ERBB2) tyrosine kinase domain activating mutations who have received prior systemic therapy. Learn more: hubs.ly/Q03V4W3n0

OncLearnNetwork's tweet image. The FDA has granted accelerated approval to #sevabertinib for adults with locally advanced or metastatic non-squamous #NSCLC harboring HER2 (ERBB2) tyrosine kinase domain activating mutations who have received prior systemic therapy. Learn more: hubs.ly/Q03V4W3n0

In a real-world setting, #CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with #FL. Learn more: hubs.ly/Q03V2BSz0

OncLearnNetwork's tweet image. In a real-world setting, #CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with #FL. Learn more: hubs.ly/Q03V2BSz0

Based on results from the ANDROMEDA trial, the FDA has approved daratumumab and hyaluronidase in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed patients with light chain amyloidosis. Learn more: hubs.ly/Q03V2TSr0

OncLearnNetwork's tweet image. Based on results from the ANDROMEDA trial, the FDA has approved daratumumab and hyaluronidase in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed patients with light chain amyloidosis. Learn more: hubs.ly/Q03V2TSr0

On November 19, 2025, the FDA approved #selumetinib for adults with #neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. Learn more: hubs.ly/Q03V0cpB0

OncLearnNetwork's tweet image. On November 19, 2025, the FDA approved #selumetinib for adults with #neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. Learn more: hubs.ly/Q03V0cpB0

As presented at #ASCP25, CytoRich Red performed better than formalin as a collecting medium for #PCR sequencing among patients with advanced #NSCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

OncLearnNetwork's tweet image. As presented at #ASCP25, CytoRich Red performed better than formalin as a collecting medium for #PCR sequencing among patients with advanced #NSCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

High-risk CSCC demands collaboration. Join experts from dermatology, oncology, and surgery as they break down real-world strategies for care coordination, IO integration, and precision treatment planning. Free Virtual Summit | Dec 4 Save Your Free Spot → hubs.ly/Q03TStSC0

OncLearnNetwork's tweet image. High-risk CSCC demands collaboration. Join experts from dermatology, oncology, and surgery as they break down real-world strategies for care coordination, IO integration, and precision treatment planning.

Free Virtual Summit | Dec 4
Save Your Free Spot → hubs.ly/Q03TStSC0

Keeping pace with rapid shifts in GI, GU, & gynecologic cancer care isn’t easy. Join #OLNAPPInstitute to learn how leading #APPs are tackling real-world challenges & refining treatment decisions with clarity and confidence. Register free: hubs.ly/Q03TVcJR0 #APPeducation

OncLearnNetwork's tweet image. Keeping pace with rapid shifts in GI, GU, & gynecologic cancer care isn’t easy.

Join #OLNAPPInstitute to learn how leading #APPs are tackling real-world challenges & refining treatment decisions with clarity and confidence.

Register free: hubs.ly/Q03TVcJR0

#APPeducation

Loading...

Something went wrong.


Something went wrong.